Skip to main content
 
Notice: Users may be experiencing issues with displaying some pages on stanfordhealthcare.org. We are working closely with our technical teams to resolve the issue as quickly as possible. Thank you for your patience.
Stanford Health Care

NCCN Guidelines Insights: Gastrointestinal Stromal Tumors, Version 2.2022.

NCCN Guidelines Insights: Gastrointestinal Stromal Tumors, Version 2.2022. Journal of the National Comprehensive Cancer Network : JNCCN von Mehren, M., Kane, J. M., Riedel, R. F., Sicklick, J. K., Pollack, S. M., Agulnik, M., Bui, M. M., Carr-Ascher, J., Choy, E., Connelly, M., Dry, S., Ganjoo, K. N., Gonzalez, R. J., Holder, A., Homsi, J., Keedy, V., Kelly, C. M., Kim, E., Liebner, D., McCarter, M., McGarry, S. V., Mesko, N. W., Meyer, C., Pappo, A. S., Parkes, A. M., Petersen, I. A., Poppe, M., Schuetze, S., Shabason, J., Spraker, M. B., Zimel, M., Bergman, M. A., Sundar, H., Hang, L. E. 2022; 20 (11): 1204-1214

Abstract

Gastrointestinal stromal tumors (GIST) are the most common type of soft tissue sarcoma that occur throughout the gastrointestinal tract. Most of these tumors are caused by oncogenic activating mutations in the KIT or PDGFRA genes. The NCCN Guidelines for GIST provide recommendations for the diagnosis, evaluation, treatment, and follow-up of patients with these tumors. These NCCN Guidelines Insights summarize the panel discussion behind recent important updates to the guidelines, including revised systemic therapy options for unresectable, progressive, or metastatic GIST based on mutational status, and updated recommendations for the management of GIST that develop resistance to specific tyrosine kinase inhibitors.

View details for DOI 10.6004/jnccn.2022.0058

View details for PubMedID 36351335